Clinical Trial Update: A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study evaluating off-the-shelf natural killer cells SAR445419 for relapsed/refractory acute myeloid leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• SAR445419

Snippet

Sponsor: Sanofi | Conditions: Acute Myeloid Leukaemia | Phase 1 | Status: TERMINATED